Tiger Brokers

BUZZ-Agios Pharma rises after US FDA expands use of co's drug for blood disorder

Reuters
Yesterday
BUZZ-Agios Pharma rises after US FDA expands use of co's drug for blood disorder

** Shares of drugmaker Agios Pharmaceuticals AGIO.O rise 8.6% to $26.70 premarket

** Company said late on Tuesday that the U.S. Food and Drug Administration has approved the expanded use of its drug for treatment of a type of blood disorder

** The drug, mitapivat, under brand name of Aqvesme, was being tested for the treatment of anemia in adults with alpha- or beta-thalassemia

** The inherited condition affects the body's ability to produce hemoglobin and healthy red blood cells

** Mitapivat was approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd

** As of last close, stock down 25.2% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10